Immuron (ASX:IMC) YoY EBITDA Growth: 36.36% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Immuron YoY EBITDA Growth?

Immuron ASX:IMC +3.13% YoY EBITDA Growth is 36.36% as of Dec. 2025. The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Immuron's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 36.36%.

Immuron's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.01.

Immuron YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Immuron's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuron YoY EBITDA Growth Chart

Immuron Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -137.50 68.42 -33.33 -87.50 26.67

Immuron Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -162.50 -22.22 42.86 36.36

Immuron YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Immuron's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.022--0.03)/ | -0.03 |
=26.67 %

Immuron's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.007--0.011)/ | -0.011 |
=36.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 36.36% mean?
Immuron (ASX:IMC) has a YoY EBITDA Growth of 36.36% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Immuron and its competitors.
Is Immuron's YoY EBITDA Growth too high?
Immuron's current YoY EBITDA Growth is 36.36%.
How does Immuron's YoY EBITDA Growth compare to VRTX and REGN?
Immuron's YoY EBITDA Growth of 36.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Immuron and its competitors. Immuron's current YoY EBITDA Growth is 36.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Immuron (ASX:IMC) has a current YoY EBITDA Growth of 36.36%. The current YoY EBITDA Growth is 36.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Immuron (ASX:IMC), the current YoY EBITDA Growth is 36.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immuron Business Description

Other Exchanges IMRN:USAANW:Germany
Address 25-37, Chapman Street, Unit 10, Blackburn, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.